| Major findings and recent advances in virus–like particle (VLP)-based vaccines MO Mohsen, L Zha, G Cabral-Miranda, MF Bachmann Seminars in immunology 34, 123-132, 2017 | 538 | 2017 |
| Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ... Annals of medicine 54 (1), 524-540, 2022 | 387 | 2022 |
| On iron metabolism and its regulation ACS Vogt, T Arsiwala, M Mohsen, M Vogel, V Manolova, MF Bachmann International journal of molecular sciences 22 (9), 4591, 2021 | 250 | 2021 |
| Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system MO Mohsen, AC Gomes, M Vogel, MF Bachmann Vaccines 6 (3), 37, 2018 | 167 | 2018 |
| Harnessing nanoparticles for immunomodulation and vaccines AC Gomes, M Mohsen, MF Bachmann Vaccines 5 (1), 6, 2017 | 160 | 2017 |
| Virus-like particle vaccinology, from bench to bedside MO Mohsen, MF Bachmann Cellular & molecular immunology 19 (9), 993-1011, 2022 | 109 | 2022 |
| Virus‐like particles for vaccination against cancer MO Mohsen, DE Speiser, A Knuth, MF Bachmann Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 12 (1 …, 2020 | 95 | 2020 |
| Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination MO Mohsen, AC Gomes, G Cabral-Miranda, CC Krueger, FMS Leoratti, ... Journal of controlled release 251, 92-100, 2017 | 90 | 2017 |
| The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics” MO Mohsen, G Augusto, MF Bachmann Immunological reviews 296 (1), 155-168, 2020 | 78 | 2020 |
| In vitro data suggest that Indian delta variant B. 1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion G Augusto, MO Mohsen, S Zinkhan, X Liu, M Vogel, MF Bachmann Allergy 77 (1), 111-117, 2022 | 72 | 2022 |
| Vaccination with nanoparticles combined with micro-adjuvants protects against cancer MO Mohsen, MD Heath, G Cabral-Miranda, C Lipp, A Zeltins, M Sande, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 66 | 2019 |
| Green ZnO nanorod material for dye degradation and detoxification of pharmaceutical wastes in water R Mohammed, MEM Ali, E Gomaa, M Mohsen Journal of Environmental Chemical Engineering 8 (5), 104295, 2020 | 59 | 2020 |
| SARS-CoV-2 structural features may explain limited neutralizing-antibody responses MF Bachmann, MO Mohsen, L Zha, M Vogel, DE Speiser npj Vaccines 6 (1), 2, 2021 | 58 | 2021 |
| Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases L Klimek, T Kündig, MF Kramer, S Guethoff, E Jensen-Jarolim, ... Allergo journal international 27, 245-255, 2018 | 58 | 2018 |
| Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine MO Mohsen, M Vogel, C Riether, J Muller, S Salatino, N Ternette, ... Frontiers in immunology 10, 1015, 2019 | 50 | 2019 |
| Zika virus-derived E-DIII protein displayed on immunologically optimized VLPs induces neutralizing antibodies without causing enhancement of dengue virus infection G Cabral-Miranda, SM Lim, MO Mohsen, IV Pobelov, ES Roesti, ... Vaccines 7 (3), 72, 2019 | 49 | 2019 |
| Alzheimer’s disease: a brief history of immunotherapies targeting amyloid β ACS Vogt, GT Jennings, MO Mohsen, M Vogel, MF Bachmann International journal of molecular sciences 24 (4), 3895, 2023 | 45 | 2023 |
| A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2 MO Mohsen, I Balke, S Zinkhan, V Zeltina, X Liu, X Chang, PS Krenger, ... Allergy 77 (1), 243-257, 2022 | 38 | 2022 |
| BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced X Chang, GS Augusto, X Liu, TM Kündig, M Vogel, MO Mohsen, ... Allergy 76 (9), 2895, 2021 | 38 | 2021 |
| The impact of size on particle drainage dynamics and antibody response S Zinkhan, A Ogrina, I Balke, G Reseviča, A Zeltins, S de Brot, C Lipp, ... Journal of controlled release 331, 296-308, 2021 | 37 | 2021 |
Daniel E. SpeiserProfessor in Immunology and Oncology在 dspeiser.ch 的电子邮件经过验证
